Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net revenue	$ 174,282	$ 136,786	$ 502,861	$ 399,098
Operating expenses:
Cost of revenue	65,794	43,767	186,446	125,111
Research and development	23,187	34,536	108,408	100,276
Selling, general and administrative	62,528	43,396	178,954	127,049
Total operating expenses	151,509	121,699	473,808	352,436
Income from operations	22,773	15,087	29,053	46,662
Co-promotion income	4,423	3,750	12,241	6,250
Interest expense	(3,765)	(3,605)	(11,143)	(4,389)
Other income	383	204	1,186	963
Income before income taxes	23,814	15,436	31,337	49,486
Provision for income taxes	(16,068)	(6,172)	(17,163)	(18,897)
Net income	7,746	9,264	14,174	30,589
Net loss attributable to non-controlling interest	47	1	140	2
Net income attributable to The Medicines Company	$ 7,793	$ 9,265	$ 14,314	$ 30,591
Basic earnings per common share attributable to The Medicines Company (USD per share)	$ 0.13	$ 0.18	$ 0.25	$ 0.57
Diluted earnings per common share attributable to The Medicines Company (USD per share)	$ 0.12	$ 0.17	$ 0.24	$ 0.55
Weighted average number of common shares outstanding:
Basic (shares)	59,231	52,896	56,296	53,653
Diluted (shares)	63,173	55,145	60,510	55,455